Tags

Type your tag names separated by a space and hit enter

Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study.
Climacteric. 2022 Apr 07 [Online ahead of print]C

Abstract

OBJECTIVE

This study aimed to evaluate the safety and efficacy of vulvovaginal intradermal injections of polynucleotides (PN) combined with hyaluronic acid (HA) in postmenopausal women affected by vulvovaginal atrophy (VVA).

MATERIALS AND METHODS

Postmenopausal women affected by VVA were treated with vulvar and vaginal intradermal injections of one prefilled syringe of 2 ml PN/HA every 2 weeks for four sessions. Patients were evaluated at T0 (baseline), T1 (after session 4) and T2 (1 month after session 4). Evaluation of the treatment was assessed by three international validated questionnaires: Vaginal Health Index (VHI), Vulvar Health Index (VuHI) and Female Sexual Function Index (FSFI). The Wilcoxon matched-paired signed-rank test was used to compare the differences in VHI, VuHI, FSFI and FSFI domains within the groups. Statistical significance was set at p < 0.05.

RESULTS

Fifty patients were included in the study (mean age 59.9 ± 7.6 years). Overall, the VHI, VuHI and FSFI reported statistically significant differences between baseline and T1 (p < 0.001) and between baseline and T2 (p < 0.001). All FSFI domains registered a statistically significant increase between baseline and T2 (p < 0.001). No complications or side effects were observed.

CONCLUSIONS

Vulvovaginal intradermal injection of PN/HA is a safe, effective treatment, is not expensive and is a reproducible procedure in postmenopausal women with VVA.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Casa di cura Santa Famiglia, Rome, Italy.Aesthetic Medicine Center, Gruppo Bios, Rome, Italy.Aesthetic Medicine Center, Ospedale San Giovanni Calibita Fatebenefratelli, Rome, Italy.Aesthetic Medicine Center, Ospedale San Giovanni Calibita Fatebenefratelli, Rome, Italy.Mathsly Research, Brescia, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35389304

Citation

Angelucci, M, et al. "Efficacy of Intradermal Hyaluronic Acid Plus Polynucleotides in Vulvovaginal Atrophy: a Pilot Study." Climacteric : the Journal of the International Menopause Society, 2022, pp. 1-7.
Angelucci M, Frascani F, Franceschelli A, et al. Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study. Climacteric. 2022.
Angelucci, M., Frascani, F., Franceschelli, A., Lusi, A., & Garo, M. L. (2022). Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study. Climacteric : the Journal of the International Menopause Society, 1-7. https://doi.org/10.1080/13697137.2022.2052840
Angelucci M, et al. Efficacy of Intradermal Hyaluronic Acid Plus Polynucleotides in Vulvovaginal Atrophy: a Pilot Study. Climacteric. 2022 Apr 7;1-7. PubMed PMID: 35389304.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of intradermal hyaluronic acid plus polynucleotides in vulvovaginal atrophy: a pilot study. AU - Angelucci,M, AU - Frascani,F, AU - Franceschelli,A, AU - Lusi,A, AU - Garo,M L, Y1 - 2022/04/07/ PY - 2022/4/7/entrez PY - 2022/4/8/pubmed PY - 2022/4/8/medline KW - Vulvovaginal atrophy KW - hyaluronic acid KW - menopause KW - polynucleotides KW - vulvar biostimulation SP - 1 EP - 7 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric N2 - OBJECTIVE: This study aimed to evaluate the safety and efficacy of vulvovaginal intradermal injections of polynucleotides (PN) combined with hyaluronic acid (HA) in postmenopausal women affected by vulvovaginal atrophy (VVA). MATERIALS AND METHODS: Postmenopausal women affected by VVA were treated with vulvar and vaginal intradermal injections of one prefilled syringe of 2 ml PN/HA every 2 weeks for four sessions. Patients were evaluated at T0 (baseline), T1 (after session 4) and T2 (1 month after session 4). Evaluation of the treatment was assessed by three international validated questionnaires: Vaginal Health Index (VHI), Vulvar Health Index (VuHI) and Female Sexual Function Index (FSFI). The Wilcoxon matched-paired signed-rank test was used to compare the differences in VHI, VuHI, FSFI and FSFI domains within the groups. Statistical significance was set at p < 0.05. RESULTS: Fifty patients were included in the study (mean age 59.9 ± 7.6 years). Overall, the VHI, VuHI and FSFI reported statistically significant differences between baseline and T1 (p < 0.001) and between baseline and T2 (p < 0.001). All FSFI domains registered a statistically significant increase between baseline and T2 (p < 0.001). No complications or side effects were observed. CONCLUSIONS: Vulvovaginal intradermal injection of PN/HA is a safe, effective treatment, is not expensive and is a reproducible procedure in postmenopausal women with VVA. SN - 1473-0804 UR - https://www.unboundmedicine.com/medline/citation/35389304/Efficacy_of_intradermal_hyaluronic_acid_plus_polynucleotides_in_vulvovaginal_atrophy:_a_pilot_study. L2 - https://www.tandfonline.com/doi/full/10.1080/13697137.2022.2052840 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.